Loading
A phase 2 trial of Vebreltinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. is a phase 2 interventional study registered as NCT06574347 by Avistone Biotechnology Co., Ltd., with 120 participants planned, started 2024-08-07 and due to reach its primary completion in 2026-10-31. Interventions recorded: Vebreltinib, Osimertinib, PLB1004. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Avistone Biotechnology, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Avistone Biotechnology, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Avistone Biotechnology, Vebreltinib, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.